Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...
A yearly injection to protect against HIV is safe and shows promise as a prevention method with long-lasting effects, ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...
An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.
Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure.
FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...
Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...
The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.
Management provided guidance of $115 million in U.S. BRIUMVI net revenue for Q1 2025 and reiterated the full-year 2025 target of $525 million. January and February 2025 were noted as the highest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results